SLC5A2 and type 2 diabetes mellitus: The introduction of sodium-glucose-cotransporter 2 inhibitors (SGLT2i) as a novel treatment option for non-insulin-dependent diabetes (NIDDM) revolutionized the management of NIDDM, as it substantially improved overall and cardiovascular outcome among high-risk patients [2–4].